Key Research Analysts at Cantor Fitzgerald Didn’t Change their ‘Overweight’ rating for Apellis Pharmaceuticals (APLS) Shares Today. Their Target Price is $53

August 9, 2018 - By Mark Babin

Apellis Pharmaceuticals (APLS) Rating Reaffirmed

Recently, In an analyst report issued to clients and investors on Wednesday, 8 August, Apellis Pharmaceuticals (APLS) shares have had their Overweight Rating kept by professional analysts at Cantor Fitzgerald, who currently has a $53 TP on company. This target by Cantor Fitzgerald suggests the possibile upside of 194.12 % from the current price.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Coverage

Among 4 analysts covering Apellis Pharmaceuticals Inc (APLS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Apellis Pharmaceuticals Inc has $53 highest and $2700 lowest target. $36.40’s average target is 102.00% above currents $18.02 stock price. Apellis Pharmaceuticals Inc had 13 analyst reports since February 23, 2018 according to SRatingsIntel. Cantor Fitzgerald initiated Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) on Wednesday, May 23 with “Buy” rating. The firm has “Hold” rating by FBR Capital given on Wednesday, June 27. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, June 26. Cantor Fitzgerald maintained Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) on Thursday, June 7 with “Buy” rating. FBR Capital downgraded the shares of APLS in report on Wednesday, April 11 to “Hold” rating. FBR Capital maintained Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) on Friday, February 23 with “Buy” rating. The stock of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) earned “Buy” rating by FBR Capital on Tuesday, March 20. The rating was upgraded by FBR Capital on Monday, July 30 to “Buy”. As per Wednesday, August 8, the company rating was maintained by Cantor Fitzgerald.

The stock increased 3.27% or $0.57 during the last trading session, reaching $18.02. About 159,228 shares traded. Apellis Pharmaceuticals, Inc. (APLS) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to report earnings on October, 30. After $-0.61 actual earnings per share reported by Apellis Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.28 % negative EPS growth.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.01 billion. The Company’s lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. It currently has negative earnings. The firm develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin.

More recent Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news were published by: Nasdaq.com which released: “Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with …” on July 24, 2018. Also Benzinga.com published the news titled: “Benzinga’s Top Upgrades, Downgrades For July 30, 2018” on July 30, 2018. Benzinga.com‘s news article titled: “50 Biggest Movers From Yesterday” with publication date: July 31, 2018 was also an interesting one.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.